Last reviewed · How we verify

NCT04950023

Small Bioactive Molecules in Early COPD Diseases

Status unknown Last updated 14 July 2021
What this trial tests

trial in Chronic Obstructive Pulmonary Disease in 550 participants. Status unknown.

Timeline
11 May 2021
Primary endpoint
11 May 2022
11 May 2024

Quick facts

Lead sponsorPeking University Third Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment550
Start date11 May 2021
Primary completion11 May 2022
Estimated completion11 May 2024
Sites1 location across China

Conditions studied

Sponsor

Peking University Third Hospital

Who can join

Under 60, any sex, with Chronic Obstructive Pulmonary Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To study the predictors contribute to the progression of COPD by follow-up of patients with early COPD and analyze their changes in bioactive molecular, exhaled gas, CT image, lung function, patient's symptoms and life quality.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Chronic Obstructive Pulmonary Disease

Currently open trials in the same condition.

Other Peking University Third Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04950023.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing